Infliximab therapy for three adolescent patients with refractory Takayasu's arteritis

Japanese Journal of Clinical Immunology

Volumn 33, Issue 6, 2010, Pages 317-323

  Kaneko, Utako ^a   Kishi, Takayuki ^a   Kikuchi, Masako ^a   Hara, Ryoki ^a   Shinoki, Toshihiko ^a   Miyamae, Takako ^a   Imagawa, Tomoyuki ^a   Mori, Masaaki ^a   Yokota, Shumpei ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Adolescent; Infliximab; Secondary failure; Takayasu's arteritis

Indexed keywords

INFLIXIMAB;

ADOLESCENT; ADVERSE DRUG REACTION; AORTA ARCH SYNDROME; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; INFUSION REACTION;

ADOLESCENT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; TAKAYASU ARTERITIS;

EID: 78651410140     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.33.317     Document Type: Article

References (18)

1. Takayasu's arteritis 11 41-48, 2002.
2. Moriwaki R, Numano F.: Takayasu arteritis: follow-up studies for 20 years. Heart Vessels Suppl. 7: 138-145, 1992.
3. Lamireau T., et al.: Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis. 10(6): 745-750, 2004.
4. Sfikakis PP., et al.: Anti-TNF therapy in the management of Behcet's disease - review and basis for recommendations. Rheumatology (Oxford). 46: 736-741, 2007.
5. Burns JC., et al.: Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 153: 833-838, 2008.
6. Booth A., et al.: Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 15: 717-721, 2004.
7. Molloy ES., et al.: Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis. 67: 1567-1569, 2008.
8. Bosch X., et al.: Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA. 8; 298: 655-669, 2007. (Pubitemid 47236417)
9. Ozen S., et al.: Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. J Pediatr. 150: 72-76, 2007. (Pubitemid 44940894)
10. Park MC., et al.: Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford). 45: 545-548, 2006.
11. Tripathy NK., et al.: Cytokine mRNA repertoire of peripheral blood mononuclear cells in Takayasu's arteritis. Clin Exp Immunol. 138: 369-374, 2004. (Pubitemid 39472458)
12. Uthman I., et al.: Successful retreatment with infliximab in patients with prior severe infusion reactions. Clin Rheumatol.25: 540-541, 2006. (Pubitemid 44137630)
13. Cheifetz A., et al.: The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 98: 1315-1324, 2003. (Pubitemid 36741529)
14. Wolbink GJ., et al.: Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 54: 711-715, 2006.
15. Bendtzen K., et al.: Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 54: 3782-3789, 2006. (Pubitemid 44955878)
16. Filocamo G., et al.: Treatment of Takayasu's arteritis with tumor necrosis factor antagonists. J Pediatr. 153: 432-434, 2008.